ProMIS Neurosci Receives a Buy from Mackie Research

By Jason Carr

Today, an analyst has provided a rating update for the Healthcare company, ProMIS Neurosci (TSX: PMN). Analyst Andre Uddin from Mackie Research rated ProMIS Neurosci (TSX: PMN) a Buy.

According to TipRanks.com, Uddin is a 3-star analyst with an average return of 32.5% and a 50.0% success rate. Uddin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Aurinia Pharmaceuticals, and Cardiome Pharma Corp.

ProMIS Neurosci has an analyst consensus of Moderate Buy.

ProMIS Neurosci’s market cap is currently C$48.14M and has a P/E ratio of 0.

ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis.

The company’s shares closed on Monday at C$0.23.